Wanbangde: Announcement on the company’s estimated guarantee amount for 2026
Securities code: 002082 Securities abbreviation: Wanbangde Announcement number: 2026-023
Wanbangde Pharmaceutical Holding Group Co., Ltd.
Announcement on the Company’s Guarantee Amount Estimation for 2026
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.
Special reminder
The estimated total external guarantee for this guarantee exceeds 50% of the listed company’s latest audited net assets.
Among the guaranteed objects, there are subsidiaries with an asset-liability ratio exceeding 70%.
The company has no external guarantees beyond the scope of the consolidated statements. Investors are kindly requested to pay attention to the relevant risks.
1. Overview of guarantee situation
Wanbangde Pharmaceutical Holdings Group Co., Ltd. (hereinafter referred to as the "Company" and "Wanbangde Pharmaceutical Holdings") held the 21st meeting of the ninth board of directors on April 28, 2026, and reviewed and approved the "Proposal on the Company's Guarantee Amount Estimate for 2026". The relevant matters are now announced as follows:
1． In order to meet the daily operation and business development needs of its subordinate holding companies, the company plans to provide a total guarantee line of no more than the equivalent of RMB 2.1 billion for companies within the scope of consolidated statements in 2026, including legal persons or other organizations newly included in the scope of consolidated statements during the authorization period.
- The guarantee authorization is valid from the date when this proposal is reviewed and approved by the shareholders' meeting to the date of the 2026 annual shareholders' meeting. The guarantee limit can be used on a rolling basis within the validity period of the authorization, and the guarantee balance at any point in time shall not exceed the guarantee limit approved by the shareholders' meeting. Within the scope of the total guarantee limit, the guarantee limit of the company's subsidiary holding companies can be adjusted according to the actual situation. Among them, a holding subsidiary with an asset-liability ratio of more than 70% can only obtain a guarantee limit from a holding subsidiary with an asset-liability ratio of more than 70% at the time of the shareholders' meeting.
3． Guarantee methods include but are not limited to guarantees, mortgages, pledges, etc.; the actual guarantee amount, type, method and term shall be subject to the final signed guarantee contract. The company's board of directors requested the shareholders' meeting to authorize the company's operating management to sign relevant legal documents within the limit on the premise of approving the above guarantee matters.
4． According to relevant regulations such as the "Supervisory Guidelines for Listed Companies No. 8 - Supervisory Requirements for Capital Transactions and External Guarantees of Listed Companies", the Stock Listing Rules of the Shenzhen Stock Exchange and the Articles of Association, this proposal still needs to be submitted to the company's shareholders' meeting for review and approval.
2. Estimated guarantee amount
Unit: Guarantee amount of 10,000 yuan
As of this time, does the guaranteed party hold the largest share of the company?
Guaranteed party Secured party Assets in the most recent period Guarantee balance Guaranteed amount Ratio of related shares Net in the most recent period
Debt ratio (10,000 yuan) (10,000 yuan) Guarantee
Asset ratio
- The company provides guarantee for subsidiaries with an asset-liability ratio of less than 70%.
Vanbond Pharmaceuticals
Controlled by and under its subordinates 100% 44% 92,853 150,000 59.62% No
joint stock company
Wanbond Medical Wanbang Medical
Pharmaceutical Holdings Technology and its subsidiaries
Asset-liability ratio 51% 69.29% 0 20,000 4.77% No Below 70%
holding company
- The company provides guarantee for subsidiaries with an asset-liability ratio of over 70%.
Wanbunde health
Technology and below
Wanbond doctor
Assets and liabilities 100% 88.63% 6,676 40,000 11.13% Fuyao Holdings
rate above 70%
holding company
3. Basic information of the guaranteed person
- Wanbangde Pharmaceutical Group Co., Ltd.
Company type: Limited liability company
Legal representative: Zhao Shouming
Registered capital: RMB 360 million
Date of establishment: July 29, 2002
Residence: No. 28, Baizhang North Road, Chengdong Street, Wenling City, Taizhou City, Zhejiang Province
Equity structure: The company directly holds 100% equity of Wanbangde Pharmaceutical
Business scope: Licensed projects: pharmaceutical production; production of Class III medical devices; operation of Class III medical devices; drug Internet information services (projects that require approval according to law can only be carried out with the approval of relevant departments, and specific business projects are subject to the approval results). General projects: technical services, technology development, technical consultation, technology exchange, technology transfer, technology promotion; sales of chemical products (excluding licensed chemical products); sales of industrial textile products; sales of instruments and meters; sales of packaging materials and products (except for projects that require approval according to law, business activities can be carried out independently with a business license in accordance with the law). (The branch office is located at: No. 18, Beisha Road, Shitang Town, Wenling City, Taizhou City, Zhejiang Province)
Main financial data: As of December 31, 2025, the company's total assets were 2.763 billion yuan, total liabilities were 1.216 billion yuan, and net assets were 1.544 billion yuan; in 2025, the company's main business income was 651 million yuan, total profit was -63.8579 million yuan, and net profit attributable to the parent was -61.8534 million yuan.
Latest credit rating status: The guaranteed credit status is good.
- Wenling Wanbangde Health Technology Co., Ltd.
Company type: Limited liability company
Legal representative: Zhao Shouming
Registered capital: RMB 50 million
Date of establishment: July 23, 2018
Residence: Second floor, Building A, No. 58, Jinhu Road, Chengdong Street, Wenling City, Taizhou City, Zhejiang Province (self-reported) Equity structure: The company directly holds 100% equity of Wanbangde Health
Business scope: Licensed items: health food production; drug production; drug wholesale; drug commissioned production; drug import and export; drug retail; third-class medical equipment leasing; third-class medical device production; third-class medical device operation; cosmetics production; food Internet sales; drug Internet information services; sales of pharmaceutical precursor chemicals sales; production of sanitary products and disposable medical supplies; Internet information services for medical devices; production of Class II medical devices; production of protective equipment for medical staff (Class II medical devices); production of medical masks (items that require approval according to law can only be carried out with the approval of relevant departments, and specific business projects are subject to the approval results). General items: sales of Class I medical devices; leasing of Class I medical devices; production of Class I medical devices; leasing of Class II medical devices; sales of Class II medical devices; wholesale of cosmetics; retail sales of cosmetics; sales of sanitary products and disposable medical supplies; leasing of non-residential real estate; production of protective supplies for medical staff (Class I medical devices); retail of medical masks; retail of protective supplies for medical staff (except for items that require approval according to law, business activities can be carried out independently with a business license in accordance with the law).
Main financial data: As of December 31, 2025, the company's total assets were 1.697 billion yuan, total liabilities were 1.504 billion yuan, and net assets were 105 million yuan; in 2025, the company's main business income was 467 million yuan, total profit was -100 million yuan, and net profit attributable to the parent company was -110 million yuan.
Latest credit rating status: The guaranteed credit status is good.
- Wanbangde Medical Technology Co., Ltd.
Company type: Limited liability company (natural person investment or holding)
Legal representative: Zhao Shouming
Registered capital: RMB 200 million
Date of establishment: January 12, 2016
Residence: 4th Floor, Building A, No. 58, Jinhu Road, Chengdong Street, Wenling City, Taizhou City, Zhejiang Province (self-declaration)
Equity structure: Wanbangde Medical Technology is a holding subsidiary of the company. The company holds 51% of the shares, related party Wanbangde Investment Co., Ltd. holds 30% of the shares, related party Zhao Shouming holds 11.4% of the shares, and related party Zhuang Hui holds 7.6% of the shares.
Business scope: Licensed projects: production of Class II medical devices; operation of Class III medical devices; production of Class III medical devices (projects that require approval according to law can only be carried out with the approval of relevant departments, and specific business projects are subject to the approval results). General projects: technical services, technology development, technical consultation, technology exchange, technology transfer, technology promotion; sales of Class II medical devices; medical research and experimental development; production of Class I medical devices; sales of Class I medical devices; production of daily masks (non-medical); daily masks ( Non-medical) sales; production of special labor protection products; sales of special labor protection products; manufacturing of industrial textile products; sales of industrial textile products; import and export of goods; import and export of technology (except for projects that require approval according to law, business activities can be carried out independently with a business license in accordance with the law).
Main financial data: As of December 31, 2025, the company's total assets were 783 million yuan, total liabilities were 542 million yuan, and net assets were 218 million yuan; in 2025, the company's main business income was 543 million yuan, total profit was -15.321 million yuan, and net profit attributable to the parent company was -3.5158 million yuan.
Latest credit rating status: The guaranteed credit status is good.
4. Main contents of the guarantee agreement
The estimated partial amount of this guarantee is based on the actual financing situation for the authorization procedures for the existing guarantee matters in the previous year. The relevant guarantee agreement has not yet been signed for the proposed guarantee matters. The main content of the guarantee agreement will be determined based on the contract signed after final negotiation between the company and its subsidiaries and the relevant financial institutions. The final actual total guarantee amount will not exceed the guarantee amount granted this time.
5. Review opinions of the board of directors
The board of directors believes that the amount of this guarantee is expected to meet the capital needs of the company and its subordinate holding companies in the operation process. They are guarantees within the scope of the company's consolidated statements. They will not have an adverse impact on the company or the company's ability to continue operating. There is no violation of relevant regulations such as "Supervisory Guidelines for Listed Companies No. 8 - Supervisory Requirements for Capital Transactions and External Guarantees of Listed Companies".
The company has absolute control over the daily production and operation activities of its subordinate holding companies. Currently, the company and its subordinate holding companies are in stable operating conditions, with good credit standing and controllable guarantee risks.
In view of the fact that the company's actual controllers Zhao Shouming and Zhuang Hui and the controlling shareholder Wanbangde Group Co., Ltd. have provided free guarantees for the company in order to support the business development of the listed company, the balance of the guarantee provided to the company as of the end of 2025 is 740.85 million yuan. Other shareholders of the company's holding subsidiary Wanbangde Medical Technology did not provide guarantees in proportion to their capital contribution, but provided full counter-guarantee measures to the company, which will not harm the interests of the company and small and medium-sized investors.
6. Cumulative number of external guarantees and number of overdue guarantees
As of December 31, 2025, the company's external guarantee balance was RMB 995.29 million, all of which were guarantees within the scope of the company's consolidated statements, accounting for 39.56% of the company's audited net assets in 2025. Except for the above guarantees, the company and its subsidiaries have no other external guarantees, and there are no overdue guarantees, guarantees involved in litigation, or losses due to the failure of the guarantee judgment.
7. Documents for reference
- Resolution of the 21st meeting of the 9th Board of Directors.
Announcement is hereby made.
Board of Directors of Wanbangde Pharmaceutical Holding Group Co., Ltd.
April 30, 2026